Introduction
Although sarcoidosis is fairly common with diverse clinical manifestations, abnormalities on the chest radiograph are usually observed during its course or first suggest the diagnosis in asymptomatic patients. A recent and important advance in diagnosing sarcoidosis has been the use of fibreoptic bronchoscopy to obtain biopsy tissue from the bronchial mucosa or adjacent lung. We report here our findings using this procedure and compare them with the results obtained using other diagnostic techniques in investigating a highly selected group of 79 consecutive patients seen at this hospital between January 1977 and December 1978 in whom sarcoidosis was diagnosed.
Patients and methods
We investigated 79 patients (40 men, 39 women). Sarcoidosis was highly probable in 55, based on the usual radiological classification: in one the chest radiograph was normal; 12 had bilateral hilar lymphadenopathy; 36 had bilateral hilar lymphadenopathy and pulmonary mottling; and six had pulmonary mottling alone. In eight patients a disease other than sarcoidosis was provisionally diagnosed: pulmonary tuberculosis (three); systemic lupus erythematosus (one); cryptogenic fibrosing alveolitis (one); honeycomb lung (one); budgerigar lung (one); and Hodgkin's disease (one). No diagnosis had been reached in the 16 remaining patients, who showed the following clinical abnormalities: diffuse bilateral pulmonary shadows (nine); diffuse bilateral pulmonary mottling and pericarditis (two); enlarged cervical lymph nodes and asymmetric hilar lymphadenopathy (two); diffuse upper-zone shadow (two); and pleural effusion (one).
Lung biopsy specimens were obtained transbronchially under fluoroscopic control1 in 42 patients: four to eight specimens were taken in each case. In some patients specimens from the bronchial mucosa were also taken during the procedure; while in some patients only biopsy of the bronchial mucosa was carried out. Tissue from various other sites was obtained in a few patients (see table I ).
Kveim tests were performed in 44 patients by giving intracutaneously 0 15 ml of a test suspension prepared from spleen K19. A punch biopsy of the test site was carried out four weeks after injection.2
All tissues were fixed in 10% formol saline; serial sections were prepared and stained with haematoxylin and eosin, Ziehl-Neelsen, and Grocott stains. whereas in the remaining 24 (320%) the disease was undiagnosed or misdiagnosed and biopsy was required to obtain a diagnosis.
Epithelioid and giant-cell granulomas were found on biopsy of a cervical lymph node in 10 patients and of the skin in one. Peripheral lymph nodes may be palpable at some time in almost all cases,7 8 and it is therefore important to search for enlarged peripheral lymph nodes, subcutaneous swellings, or skin lesions, as biopsy of these may provide histological support for the diagnosis.
The Kveim tests were carried out with batches of the splenic suspension K19. Studies in 3290 patients2 have shown that K19 yields a distribution of Kveim reactivity closely in keeping with that reported previously9 10; and it has the qualities associated with validated Kveim test suspensions." Overall, under half the patients tested reacted to the suspension, and fewer reactions than would be expected occurred in patients with stage 2 disease (hilar lymphadenopathy and pulmonary mottling). This may partly be due to the well-recognised waning in Kveim reactivity among patients with sarcoidosis of more than two years' duration.' 1 Transbronchial biopsy through a fibreoptic bronchoscope has a low complication rate"2 and is comfortable for the patient.
General anaesthetic is not required. The specimens obtained are small, but special fixation techniques"3 permit accurate histological diagnosis in most cases. In the present series 37 (88%) out of 42 patients investigated by transbronchial lung biopsy showed evidence of disease. Granulomas were present in the lung specimens from all 14 patients with pulmonary mottling only or pulmonary fibrosis (stages 3 and 4) and also in specimens from two out of three patients with hilar lymphadenopathy only (stage 1). Although the rate of positive findings on transbronchial biopsy is high among patients with sarcoidosis who have radiological evidence of pulmonary infiltration, it is also high (abqut 600o) among patients with hilar lymphadenopathy whose chest radiographs show normal lungfields.14 15 Interestingly, out of 22 patients in the present study who underwent biopsy of the bronchial mucosa, 17 (77%0) had granulomas; and the bronchial mucosa often showed remarkably little scarring, even in patients with chronic pulmonary sarcoidosis associated with pulmonary fibrosis.16
In two patients granulomas were present in tissue from mediastinal lymph nodes obtained by mediastinoscopy. Taken alone this finding does not confirm the diagnosis of sarcoidosis, since it may also occur in tuberculosis, lymphoma or other malignant disease, berylliosis, brucellosis, extrinsic allergic alveolitis, histoplasmosis, collagen disorders, and antibody deficiency syndromes.1 7-19 Clinical and radiographic features, however, usually make the distinction obvious. In two patients epithelioid and giant-cell granulomas were found on liver biopsy: miliary granulomas are present in the liver in about two-thirds of all patients with sarcoidosis, but only a few patients with hepatic granulomatosis have sarcoidosis. 20 In this study we placed emphasis on tissue biopsy methods and the Kveim skin test. Nevertheless, a "blind" conjunctival biopsy will show granulomas in one-third of patients with sarcoidosis,21 and indirect methods such as gallium scanning, assaying fluid obtained by bronchial lavage, and measuring serum concentrations of angiotensin-I-converting enzyme may provide additional support for the diagnosis. In the Vero cells 1 mg of acyclovir!l reduced the yield of virus by 90%, which was slightly less than the effect on herpes simplex virus. Results in the rabbits varied with the interval between doses, duration of treatment, and delay before starting treatment. Acyclovir controlled an otherwise lethal infection when given not less than eight-hourly for 14 days. Withdrawing treatment after 9-10 days resulted in late-onset fatal disease in some rabbits. Treatment begun within 24 hours after infection gave complete protection, and rabbits first treated up to five days after infection showed a significant reduction in mortality (p< 0-001).
The plasma half life of acyclovir is twice as long in man as in rabbits and progression of the disease is much slower. Hence acyclovir may be useful for postexposure prophylaxis against B virus infection in man and possibly also for treatment of the disease. Several antiviral agents have been tested both in vitro and in vivo. For the in-vivo studies rabbits have been used; rabbits respond to subcutaneous injection of small amounts of virus with a fatal ascending encephalomyelitis that is closely similar to the disease in man after a bite from an infected monkey. Adenine arabinoside (vidarabine) was the most active antiviral compound in early in-vitro tests, but pronounced depression of viral replication occurred only with high concentrations of the drug. Thus, as expected, vidarabine had little effect on mortality in rabbits infected with B virus, though survival was prolonged if treatment was begun immediately after infection. The new nucleoside analogue acyclovir (acycloguanosine; 9-(2-hydroxyethoxymethyl) guanine; Burroughs Wellcome Co) is highly active against several herpesviruses both in vitro and in various animals.>6 It was also effective in human corneal ulcers caused by herpes simplex virus7 and in pneumonia that developed in an immunocompromised boy a few days after the onset of severe and extensive herpes labialis. 8 We describe experiments suggesting that acyclovir will be useful in postexposure prophylaxis against B virus infection in man and possibly for treating clinically evident disease. Yield-reduction test-Confluent monolayers of Vero cells in 25 cm2 plastic flasks were infected with 0-3-1-0 TCD50 of B virus/cell. The infected monolayers were washed and covered with 3 ml of medium containing appropriate concentrations of antiviral compound. After
